Advanced in Pseudobulbar Affect

Dr. Gustavo Alva

Psychiatry
Providence
302 West La Veta Avenue, Suite 202, 
Orange, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Pseudobulbar Affect
Providence
302 West La Veta Avenue, Suite 202, 
Orange, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gustavo Alva is a Psychiatrist in Orange, California. Dr. Alva is rated as an Advanced provider by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Major Depression, Bipolar Disorder (BPD), Seasonal Affective Disorder (SAD), and Generalized Anxiety Disorder (GAD). Dr. Alva is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

302 West La Veta Avenue, Suite 202, Orange, CA 92866
Call: 714-545-5550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Masupirdine (SUVN-502) for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Enrollment Status: Recruiting
Publish Date: May 20, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 07, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drug: AL002
Study Phase: Phase 2
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes
Enrollment Status: Terminated
Publish Date: December 20, 2024
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 27, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: August 10, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

16 Total Publications

Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.
Pimavanserin safety in adult and elderly patients with neuropsychiatric symptoms related to neurodegenerative disease: An open-label extension study.
Journal: Journal of Alzheimer's disease : JAD
Published: June 16, 2025
View All 16 Publications
Similar Doctors
Distinguished in Pseudobulbar Affect
Dr. Joshua K. Koh
Psychiatry
Distinguished in Pseudobulbar Affect
Dr. Joshua K. Koh
Psychiatry
2058 N Mills Ave, 
Claremont, CA 
 (24.6 miles away)
Languages Spoken:
English, Thai
See accepted insurances

Joshua Koh is a Psychiatrist in Claremont, California. Dr. Koh is rated as a Distinguished provider by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Kluver Bucy Syndrome, Pseudobulbar Affect, Seasonal Affective Disorder (SAD), and Major Depression.

Advanced in Pseudobulbar Affect
Dr. Rimal B. Bera
Psychiatry
Advanced in Pseudobulbar Affect
Dr. Rimal B. Bera
Psychiatry

The Department Of Psychiatry

101 The City Dr S, 
Orange, CA 
 (2.6 miles away)
714-456-8068
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rimal Bera is a Psychiatrist in Orange, California. Dr. Bera is rated as a Distinguished provider by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Schizophrenia, Major Depression, Bipolar Disorder (BPD), and Generalized Anxiety Disorder (GAD).

Advanced in Pseudobulbar Affect
Dr. Jason P. Kellogg
Psychiatry
Advanced in Pseudobulbar Affect
Dr. Jason P. Kellogg
Psychiatry
Irvine, CA 
 (7.2 miles away)
949-722-7118
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Kellogg is a Psychiatrist in Irvine, California. Dr. Kellogg is rated as a Distinguished provider by MediFind in the treatment of Pseudobulbar Affect. His top areas of expertise are Schizophrenia, Major Depression, Schizoaffective Disorder, and Seasonal Affective Disorder (SAD). Dr. Kellogg is currently accepting new patients.

VIEW MORE PSEUDOBULBAR AFFECT DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alva's expertise for a condition
ConditionClose
    • Distinguished
    • Bipolar Disorder (BPD)
      Dr. Alva is
      Distinguished
      . Learn about Bipolar Disorder (BPD).
      See more Bipolar Disorder (BPD) experts
    • Major Depression
      Dr. Alva is
      Distinguished
      . Learn about Major Depression.
      See more Major Depression experts
    • Advanced
    • Alzheimer's Disease
      Dr. Alva is
      Advanced
      . Learn about Alzheimer's Disease.
      See more Alzheimer's Disease experts
    • Dementia
      Dr. Alva is
      Advanced
      . Learn about Dementia.
      See more Dementia experts
    • Generalized Anxiety Disorder (GAD)
      Dr. Alva is
      Advanced
      . Learn about Generalized Anxiety Disorder (GAD).
      See more Generalized Anxiety Disorder (GAD) experts
    • Pseudobulbar Affect
      Dr. Alva is
      Advanced
      . Learn about Pseudobulbar Affect.
      See more Pseudobulbar Affect experts
    • Schizophrenia
      Dr. Alva is
      Advanced
      . Learn about Schizophrenia.
      See more Schizophrenia experts
    • Seasonal Affective Disorder (SAD)
      Dr. Alva is
      Advanced
      . Learn about Seasonal Affective Disorder (SAD).
      See more Seasonal Affective Disorder (SAD) experts
    • Experienced
    • Asperger's Syndrome
      Dr. Alva is
      Experienced
      . Learn about Asperger's Syndrome.
      See more Asperger's Syndrome experts
    • Attention Deficit Hyperactivity Disorder (ADHD)
      Dr. Alva is
      Experienced
      . Learn about Attention Deficit Hyperactivity Disorder (ADHD).
      See more Attention Deficit Hyperactivity Disorder (ADHD) experts
    • Delirium
      Dr. Alva is
      Experienced
      . Learn about Delirium.
      See more Delirium experts
    • Obsessive-Compulsive Disorder (OCD)
      Dr. Alva is
      Experienced
      . Learn about Obsessive-Compulsive Disorder (OCD).
      See more Obsessive-Compulsive Disorder (OCD) experts
    • Post-Traumatic Stress Disorder (PTSD)
      Dr. Alva is
      Experienced
      . Learn about Post-Traumatic Stress Disorder (PTSD).
      See more Post-Traumatic Stress Disorder (PTSD) experts
    • Schizoaffective Disorder
      Dr. Alva is
      Experienced
      . Learn about Schizoaffective Disorder.
      See more Schizoaffective Disorder experts
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.